Search clinical trials for: PCSK9 INHIBITOR

Total 67850 results

National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults

Proteomics | Lipoprotein Metabolism | PCSK9

United States
Franck Boccara
Institut National de la Santé Et de la Recherche Médicale, France; Amgen; National...

Completed

COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients (COPANA)

Dyslipidemias | HIV Seropositivity | PCSK9

France
Shenzhen People's Hospital
Innovent Biopharmaceutical Co., Ltd.

Active, not recruiting

Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia

Efficacy and Safety | Heterozygous Familial Hypercholesterolemia | PCSK9

China
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)

Hepatitis C

Taiwan
Hospices Civils de Lyon

Unknown

RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin (RIBAJUSTE)

Chronic Hepatitis C

France
First Affiliated Hospital of Harbin Medical University

Recruiting

Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis

PCSK9

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

Proteomics | Lipoprotein Metabolism | PCSK9

United States
C.L.A.Vleggeert-Lankamp
Spaarne Gasthuis; Stichting Achmea Gezondheidszor; Posthumus Meyjes Fonds

Recruiting

Transforaminal Epidural Injection in Acute Sciatica (TEIAS)

Sciatica | Sciatica Due to Intervertebral Disc Disorder | Sciatic Radiculopathy

Netherlands
Bristol-Myers Squibb

Completed

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Hepatitis C

United States, Puerto Rico
Yonsei University
GE Healthcare

Completed

Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study)

Chronic Renal Failure

Korea, Republic of
Shanghai Tong Ren Hospital

Recruiting

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction (PERFECT-AMI)

Early PCSK9 Inhibitor on Ventricular Remodling

China
Shenzhen People's Hospital

Recruiting

Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study

Cardiovascular Diseases | Lipid Metabolism

China
Guangdong Provincial People's Hospital

Not yet recruiting

PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS

Colorectal Cancer
Sejong General Hospital
Samsung Medical Center; Chonnam National University Hospital; Daegu Catholic... and other collaborators

Recruiting

Evolocumab in STEMI

ST Elevation Myocardial Infarction

Korea, Republic of
Xiang Xie
Xinjiang Medical University

Not yet recruiting

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Cancer | Atherosclerotic Cardiovascular Disease | ASCVD | Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
National Medical Research Center for Therapy and...

Recruiting

Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients (PINTL)

Dyslipidemias | Hyperlipidemias | Liver Transplant Disorder | Immunosuppression | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Statins

Russian Federation
National Institute on Alcohol Abuse and Alcoholism...

Recruiting

Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

Alcohol Associated Liver Disease | Heavy Drinking Behavior

United States
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR); Biovalorem

Active, not recruiting

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer

Canada
Pauls Stradins Clinical University Hospital

Active, not recruiting

Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques

Atherosclerotic Cardiovascular Disease

Latvia
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge

Completed

INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers

Cardiovascular Diseases | Atherosclerosis

United Kingdom
Beijing Friendship Hospital
Changhai Hospital; Peking Union Medical College Hospital; Peking University Cancer...

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Locally Advanced Rectal Cancer

China
University of Erlangen-Nürnberg Medical School

Completed

Effect of Evolocumab on Vascular Function (EVO)

Atherosclerotic Cardiovascular Disease

Germany
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge

Active, not recruiting

Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease (INTENSITY-HIGH)

Cardiovascular Diseases | Atherosclerosis

United Kingdom
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Hypercholesterolemia

United States
University Of Perugia

Completed

NUtraceutical TReatment for hYpercholesterolemia in HIV-infected Patients (NU-TRY(HIV))

Inflammation | Atherosclerosis | Hypercholesterolemia
Seoul National University Hospital

Unknown

PCSK9 Inhibitors in the Progression of Aortic Stenosis

Aortic Valve Stenosis

Korea, Republic of
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Hypercholesterolemia

United States, Austria, Canada, Czech Republic, Denmark, France, Israel, Netherlands, Norway, Russian Federation, South Africa, Spain, Sweden, United Kingdom
Novartis Pharmaceuticals

Not yet recruiting

A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia
University of British Columbia
Vancouver Coastal Health Research Institute; Genome British Columbia

Recruiting

Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE)

Acute Coronary Syndrome | Familial Hypercholesterolemia | STEMI | NSTEMI - Non-ST Segment Elevation MI | Familial Hypercholesterolemia - Heterozygous | Familial Hypercholesterolemia Due to Genetic Defect of Apolipoprotein B | Familial Hypercholesterolemia Due to Heterozygous LDL Receptor Mutation and other conditions

Canada
University of Oxford
Novartis Pharmaceuticals; The TIMI Study Group

Active, not recruiting

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4)

Atherosclerotic Cardiovascular Disease

United Kingdom, United States
Nantes University Hospital

Completed

Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome. (PC-SCA-9)

Acute Coronary Syndrome

France
LIB Therapeutics LLC
Medpace, Inc.

Active, not recruiting

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (LIBerate-HR)

Cardiovascular Diseases | Hypercholesterolemia | Cardiovascular Risk Factor | Cardiovascular Stroke

United States, Israel, India
LIB Therapeutics LLC
Medpace, Inc.

Active, not recruiting

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction (LIBerate-CVD)

Cardiovascular Diseases | Hyper-LDL-cholesterolemia

United States
LIB Therapeutics LLC
Medpace, Inc.

Enrolling by invitation

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (LIBerate-OLE)

Familial Hypercholesterolemia | Elevated Cholesterol | Cardiovascular Disease With Mention of Arteriosclerosis

United States, Israel, Norway, South Africa, Turkey, India
LIB Therapeutics LLC
Medpace, Inc.

Completed

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (LIBerate-FH)

Heterozygous Familial Hypercholesterolemia

United States, Israel, Norway, South Africa, Turkey
Novartis Pharmaceuticals

Recruiting

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Primary Prevention of Atherosclerotic Cardiovascular Disease

United States, China, Italy, Spain, France, Netherlands, Poland, Switzerland, Taiwan, Greece, Thailand, Brazil, India, Hungary, Latvia, Mexico, Israel, Malaysia, Turkey, Argentina, Singapore, Australia, Belgium, Bulgaria, Denmark, Croatia, South... and more
Novartis Pharmaceuticals

Recruiting

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia (V-DIFFERENCE)

Hypercholesterolemia

Bulgaria, Germany, Spain, Estonia, Latvia, France, Poland, Czechia
LIB Therapeutics LLC
Medpace, Inc.

Completed

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

LDL Cholesterol

United States
Santaris Pharma A/S

Terminated

Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH

Hypercholesterolemia

Netherlands
Wuhan Union Hospital, China

Recruiting

A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients

Heart Transplant Failure and Rejection

China
Maastricht University Medical Center

Recruiting

PCSK9 Polymorphism and Risk of Cardiac Rupture

Post-Infarction Heart Rupture | Gene Polymorphism

Italy
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-15)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia

Japan
Pfizer

Completed

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
Ottawa Hospital Research Institute
Heart and Stroke Foundation of Ontario

Completed

Sex Hormones and Blood PCSK9 Levels

Hypercholesterolemia

Canada
Stanford University
National Heart, Lung, and Blood Institute (NHLBI)

Enrolling by invitation

PCSK9 Inhibition After Heart Transplantation

Vasculopathy

United States
Jose Seijas Amigo

Completed

Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors (MEMOGAL)

Quality of Life | Hypercholesterolemia | Cognitive Function

Spain
Instituto de Seguridad y Servicios Sociales de...

Completed

Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia (CytoEx-PCSK9)

Hypercholesterolemia, Familial

Mexico
Laval University

Completed

Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia

Familial Hypercholesterolemia

Canada
Wolfson Medical Center
Sanofi; Assaf-Harofeh Medical Center

Unknown

Treatment of Severe Infection With Antihyperlipidemia Drug

Sepsis | Septic Shock

Israel
LIB Therapeutics LLC
Medpace, Inc.

Active, not recruiting

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (LIBerate-VI)

Hypercholesterolemia | Atherosclerotic Ischemic Disease

Spain, Germany, France, Norway, United Kingdom

Search clinical trials for: PCSK9 INHIBITOR

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations